Multiple Endocrine Neoplasia: Clinical Trials

14 trials for Multiple Endocrine Neoplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 14 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 10, Terminated 2, Not yet recruiting 1, Recruiting 1
Phase 23Completed 2, Recruiting 1

Follow Multiple Endocrine Neoplasia: new trials by email Literature Review of Multiple Endocrine Neoplasia trials Research Report on Multiple Endocrine Neoplasia

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FOsfomycin for Male Urinary Tract Infection
Fosfomycun-trometamol - Urinary Tract Infection, Prostatitis
Phase 3Not yet recruitingUniversity Hospital, Rouen1382026-07-012026-06-12
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
18F-FCH, NeuroEXPLORER - Primary Hyperparathyroidism, Parathyroid Cancer
Phase 2 / Phase 3RecruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1932026-04-162026-10-29
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Evolocumab, Placebo - Coronary Heart Disease (CHD)
Phase 3CompletedAmgen123012019-06-112026-06-25
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Alectinib, Crizotinib - Neoplasms
Phase 3CompletedHoffmann-La Roche502017-07-052026-10-09
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Ribociclib, letrozole - Breast Cancer
Phase 3TerminatedNovartis Pharmaceuticals82017-06-072020-05-28
Effect of PROGRESSive Training and Teststerone in Older Frail Men
testosterone, Progressive muscle training - Muscle Weakness
Phase 2 / Phase 3CompletedUniversity Hospital, Gentofte, Copenhagen1922016-11-012024-05-29
HIV & Drug Abuse Prevention for South African Men
Soccer League (SL), Soccer League/Vocational Training (SL-V) - Substance-Related Disorders, Human Immunodeficiency Virus
Phase 3CompletedUniversity of California, Los Angeles12112016-05-012020-02-17
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Fulvestrant, Alpelisib, Placebo - Breast Cancer
Phase 3CompletedNovartis Pharmaceuticals5722015-07-232025-02-13
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Ribociclib, Fulvestrant, Placebo - Advanced Breast Cancer
Phase 3CompletedNovartis Pharmaceuticals7262015-06-092023-11-30
Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Erythromycin, Placebo, Magnetic Resonance Imaging - Healthy
Phase 2 / Phase 3CompletedMayo Clinic402011-06-012016-03-21
Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis
Timed intercourse, Microsurgical varicocelectomy, Intrauterine insemination - Pregnancy, Infertility
Phase 3TerminatedYale University32010-05-012013-07-02
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
60 mg denosumab, Placebo - Low Bone Mass, Low Bone Mineral Density
Phase 3CompletedAmgen2422009-10-012018-10-17
Cinacalcet to Treat Familial Primary Hyperparathyroidism
Parathyroid hormone testing, Serum calcium testing - Hypercalcemia, Familial Primary Hyperparathyroidism
Phase 3CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)252006-05-092017-07-02
Effectiveness of HIV Risk Reduction Program Among African American Men
Focus on the Future, Control standard of care treatment - Sexually Transmitted Diseases, HIV
Phase 3CompletedRichard Crosby2702003-04-012013-12-16

Narrower conditions

Multiple Endocrine Neoplasia Type 1 (12)  ·  Breast Neoplasms (3)  ·  Neoplasms (3)  ·  Multiple Endocrine Neoplasia Type 2a (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Alcoholism (1)  ·  Bone Diseases, Metabolic (1)  ·  Breast Diseases (1)  ·  Carcinoma, Medullary (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Coronary Disease (1)  ·  Cystitis (1)  ·  Gastrinoma (1)  ·  Hypercalcemia (1)  ·  Hyperparathyroidism 1 (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Endocrine Gland Neoplasms (14)  ·  Endocrine System Diseases (14)  ·  Genetic Diseases, Inborn (14)  ·  Neoplasms, Multiple Primary (14)  ·  Neoplastic Syndromes, Hereditary (14)  ·  Neoplasms by Site (13)  ·  Neoplasms (11)  ·  Genital Diseases (4)  ·  Urogenital Diseases (4)  ·  Infections (3)  ·  Skin Diseases (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Breast Diseases (2)

Interventions

Fulvestrant (2)  ·  ribociclib (2)  ·  Alpelisib (1)  ·  Autogenic Training (1)  ·  Crizotinib (1)  ·  Denosumab (1)  ·  Erythromycin (1)  ·  Letrozole (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Sodium Chloride (1)  ·  Surgical Procedures, Operative (1)  ·  Testosterone (1)  ·  Water (1)  ·  alectinib (1)  ·  evolocumab (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  Amgen (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  Hoffmann-La Roche (1)  ·  Mayo Clinic (1)  ·  Richard Crosby (1)  ·  University Hospital, Gentofte, Copenhagen (1)  ·  University Hospital, Rouen (1)  ·  University of California, Los Angeles (1)  ·  Yale University (1)

Countries

United States (9)  ·  France (5)  ·  Italy (4)  ·  Russia (4)  ·  South Korea (4)  ·  Spain (4)  ·  Australia (3)  ·  Austria (3)  ·  Belgium (3)  ·  Bulgaria (3)  ·  Canada (3)  ·  Czechia (3)  ·  Denmark (3)  ·  Germany (3)  ·  Hungary (3)

Top investigators

Andrew Forsythe, PhD (1)  ·  Christos Coutifaris, MD (1)  ·  Dana A Ohl, MD (1)  ·  Esther Eisenberg, MD, MPH (1)  ·  Gregory M Christman, MD (1)  ·  Heping Zhang, PhD (1)  ·  Jeff Fidler, MD (1)  ·  Karsten Overgaard, M.D. (1)  ·  Mary Jane Rotheram, PhD (1)  ·  Michael Diamond, MD (1)  ·  Nanette Santoro, MD (1)

Results publications

PMID 22130101, PMID 29500160, PMID 29860922, PMID 30075740, PMID 30653530, PMID 31091374, PMID 31305131, PMID 31826360, PMID 32106835, PMID 32416251, PMID 33246021, PMID 33769862, PMID 33780274, PMID 34102253, PMID 34158598, PMID 36380117, PMID 36800111, PMID 37653397, PMID 37673211, PMID 38439079, PMID 39177931, PMID 39259241, PMID 39289825, PMID 39826197, PMID 41211925, PMID 41903215, PMID 42153665, PMID 42183757, PMID 42334791, PMID 42663360, PMID 42670293

NIH funding

2015 (2), 2023 (2), 2017 (1), 2018 (1), P01DK068055 (1), R01DA038675 (1), R21MH066682 (1), U10HD055925 (1), U10HD055936 (1)